DCTH Q3 2024: $25M Warrant Cash Funds Trials, No $36M Raise Needed
- Strong Center Activation and Pipeline: Management highlighted a robust pipeline of centers actively engaged with treating patients—many centers are in preceptorship and activation with the expectation to reach 20 active centers in Q1 and 30 by year-end, with at least one expected to be a top performer.
- Promising Real-World Efficacy and Treatment Metrics: Field anecdotes indicate that physicians are observing response rates significantly higher than those seen in the FOCUS trial, with a consistent treatment interval of 6 to 8 weeks, suggesting strong clinical acceptance and potential for improved patient outcomes.
- Upcoming Pivotal Trial Data and Expansion into New Indications: With the CHOPIN trial nearing a data readout next year and plans to initiate two Phase II trials in colorectal and breast cancer in 2025, there is potential for important catalysts that could drive market expansion and revenue growth.
- Seasonality risks: The fourth quarter is expected to have 1.5 to 2 weeks fewer treatment days due to the holiday season, which could temporarily reduce treatment volumes and potentially impact near-term revenue growth.
- Uncertainty in center activation: The center activation process remains complex and unpredictable, with some centers taking 6 to 9 months to become fully operational. This uncertainty could delay revenue ramp-up if key centers face unforeseen delays.
- Reliance on clinical trial outcomes: Upcoming trials (e.g., CHOPIN, colorectal, and breast cancer studies) involve significant R&D investment. Uncertain or disappointing trial outcomes could hinder market adoption and delay further expansion, adversely affecting future expectations.
-
Funding Impact
Q: Are warrant funds boosting trial financing?
A: Management clarified that the $25 million received from warrant exercises, along with operational cash, will fund new trials without relying on an additional $36 million, reinforcing a strong balance sheet. -
R&D Spending
Q: How is R&D spend impacted by trials?
A: They expect Q4 R&D expenses to remain flat, with full-year 2025 projections reaching $35–40 million to cover both base costs and new indication studies, ensuring measured investment. -
Trial Outcomes
Q: What trial data is expected soon?
A: Management anticipates a CHOPIN trial data readout by mid-next year, with upcoming colorectal enrollment starting in mid-2025 and breast cancer trials later in the year, potentially advancing market adoption. -
Seasonality Impact
Q: Does the holiday season affect treatments?
A: They noted that holiday schedules will reduce treatment days by about 1.5–2 weeks, stretching treatment intervals without losing overall business. -
Regulatory Outlook
Q: Is additional FDA approval needed?
A: Management expressed confidence that current clinical practices and treatment sequencing eliminate the need for a separate FDA label expansion, easing regulatory risk. -
Center Activation
Q: How long does center activation take now?
A: They estimate an average activation time of 6 to 9 months, acknowledging variability but remaining on track to meet planned targets. -
Referral Network
Q: Are oncologist referrals growing?
A: Despite many centers still in training, there's an increasing momentum with oncologists actively referring patients, which bodes well for future growth. -
Treatment Intervals
Q: What is the current interval between treatments?
A: Most treatments are occurring every 6 to 8 weeks, with slight delays during holidays, aligning with established treatment protocols. -
Clinical Evidence
Q: What supports data for new indications?
A: Supporting evidence includes clinical results from surgical hepatic perfusion—with response rates in the high 50s–60s percent range for colorectal—and promising anecdotal outcomes in breast cancer, justifying expansion efforts.
Research analysts covering DELCATH SYSTEMS.